CRISPR Gene Editing
CRISPR technology has also been applied to the generation of physiologically relevant cell-based assays and in vivo, validating the effect of target knock-out in the context of a living organism.
CRISPR-Cas9 used under license to granted and pending US and international patents from the Broad Institute and ERS Genomics Limited.
Our adenoviral technology provides an effective delivery system suitable for both transient and long-term expression in an arrayed format for high throughput readout. In addition, the FlexSelect® Collection contains over 1,900 human full-length cDNA’s that can be used to increase the expression of genes in cells. Charles River’s collections of arrayed adenoviruses are expertly applied to therapeutic areas of interest such as respiratory, inflammation, neuroscience, oncology, and rare diseases.
The SilenceSelect® Collection contains over 19,000 shRNAs that can be used to knock-down more than 5,000 different human druggable targets representing more than 11,000 transcript variants.